KIMBERLY SCHROCK: Open Payments
NPI 1053745729 · HUTCHINSON, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,870 in 99 payments from 18 companies in 2025. Trend: 2023 $997 · 2024 $2,022 · 2025 $1,870
Food & beverage: $1,778Education: $91
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $251 |
| Regeneron Healthcare Solutions, Inc. | 22 | $194 |
| Genentech USA, Inc. | 7 | $181 |
| GlaxoSmithKline, LLC. | 11 | $176 |
| CSL Behring | 8 | $172 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $162 |
| Pharming Healthcare, Inc. | 7 | $130 |
| Novartis Pharmaceuticals Corporation | 6 | $116 |
| BioCryst US Sales Co., LLC | 3 | $99 |
| Amgen Inc. | 4 | $83 |
Products named: DUPIXENT, XOLAIR, FASENRA, RUCONEST, Andembry, OCTAGAM IMMUNE GLOBULIN (HUMAN), ORLADEYO, NUCALA.
Industry payments across KS — which companies pay providers there.
